2014
BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS
Steg P, Mehran R, Goldstein P, Witzenbichler B, Hof A, Guagliumi G, Hamm C, Genereux P, Clemmensen P, Parise H, Pocock S, Gersh B, Bernstein D, Deliargyris E, Stone G, Bichat H. BIVALIRUDIN VERSUS HEPARIN WITH OR WITHOUT GLYCOPROTEIN IIB/IIIA INHIBITORS IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A POOLED ANALYSIS OF PATIENT-LEVEL DATA FROM THE HORIZONS-AMI AND EUROMAX TRIALS. Journal Of The American College Of Cardiology 2014, 63: a34. DOI: 10.1016/s0735-1097(14)60034-6.Peer-Reviewed Original ResearchGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsPatient-level dataEUROMAX trialHORIZONS-AMIPrimary PCISTEMI patientsPooled analysisPatientsTrialsHeparin
2013
Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy
Nazif T, Mehran R, Lee E, Fahy M, Parise H, Stone G, Kirtane A. Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. American Heart Journal 2013, 167: 43-50. PMID: 24332141, DOI: 10.1016/j.ahj.2013.10.013.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa receptor inhibitorsNet adverse clinical eventsMajor adverse cardiac eventsHigh-risk acute coronary syndromesAcute coronary syndromeMajor bleedingCoronary syndromeComposite major adverse cardiac eventsIIb/IIIa receptor inhibitorsGlycoprotein IIb/IIIa inhibitorsEarly invasive management strategyIIb/IIIa inhibitorsInvasive management strategySafety of tirofibanAdverse cardiac eventsSimilar clinical outcomesAdverse clinical eventsUse of tirofibanComparative effectiveness analysisSignificant differencesACUITY trialAcute CatheterizationUpstream tirofibanMultivariable adjustmentUpstream therapyImpact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery
Wöhrle J, Brodie B, Witzenbichler B, Dudek D, Kornowski R, Metzger C, Grines C, McAndrew T, Parise H, Sergie Z, Mehran R, Stone G. Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery. The American Journal Of Cardiology 2013, 112: 753-760. PMID: 23746479, DOI: 10.1016/j.amjcard.2013.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, PhytogenicAntithrombinsCoronary AngiographyCoronary VesselsDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHirudinsHumansMaleMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPercutaneous Coronary InterventionProspective StudiesRecombinant ProteinsTreatment OutcomeConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionPaclitaxel-eluting stentingImpact of bivalirudinTarget vessel revascularizationPercutaneous coronary interventionVessel revascularizationCoronary interventionCardiac deathPrimary PCIGlycoprotein IIb/IIIa inhibitorsIschemia-driven target vessel revascularizationIIb/IIIa inhibitorsLeft anterior descending (LAD) arteryHORIZONS-AMI trialMajor bleeding eventsUse of bivalirudinAnterior descending (LAD) arteryElevation myocardial infarctionBare-metal stentingSignificant lower rateLower ratesBleeding eventsCardiovascular eventsRevascularization rates
2011
Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey T, Fahy M, Parise H, Stone G. Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 760-768. PMID: 21777884, DOI: 10.1016/j.jcin.2011.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyDiabetes MellitusDose-Response Relationship, DrugDouble-Blind MethodElectrocardiographyFemaleFollow-Up StudiesHirudinsHumansHypoglycemic AgentsMaleMiddle AgedMyocardial InfarctionPeptide FragmentsProspective StudiesRecombinant ProteinsStentsSurvival RateTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionHORIZONS-AMI trialDiabetes mellitusDiabetic patientsMyocardial infarctionPrimary PCIMajor adverse cardiac eventsIIb/IIIa inhibitorsEffectiveness of bivalirudinEfficacy of bivalirudinAdverse cardiac eventsAcute coronary syndromeElevation myocardial infarctionPercutaneous coronary interventionAcute myocardial infarctionMajor bleedingCardiac mortalityCoronary syndromeAnticoagulant therapyCardiac eventsCoronary interventionCardiac deathUnfractionated heparinHeparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Stone G, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Gersh B, Pocock S, Dangas G, Wong S, Fahy M, Parise H, Mehran R, Investigators O. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet 2011, 377: 2193-2204. PMID: 21665265, DOI: 10.1016/s0140-6736(11)60764-2.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCombined Modality TherapyConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHeparinHirudinsHumansKaplan-Meier EstimateMaleMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsStentsSurvival AnalysisTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsPercutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsBivalirudin monotherapyStent thrombosisCoronary interventionMyocardial infarctionIschaemia-driven target lesion revascularisationIschaemia-driven target vessel revascularisationMajor adverse cardiovascular eventsComposite adverse eventsHORIZONS-AMI trialPaclitaxel-eluting stentingTarget vessel revascularisationAdverse cardiovascular eventsBypass graft surgeryTarget lesion revascularisationElevation myocardial infarctionOnset of symptomsKaplan-Meier estimatesAcute myocardial infarction
2010
Impact of Transfer for Primary Percutaneous Coronary Intervention on Survival and Clinical Outcomes (from the HORIZONS-AMI Trial)
Wöhrle J, Desaga M, Metzger C, Huber K, Suryapranata H, Guetta V, Guagliumi G, Witzenbichler B, Parise H, Mehran R, Stone G. Impact of Transfer for Primary Percutaneous Coronary Intervention on Survival and Clinical Outcomes (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2010, 106: 1218-1224. PMID: 21029816, DOI: 10.1016/j.amjcard.2010.06.049.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionCoronary AngiographyFemaleHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionPatient TransferPeptide FragmentsProportional Hazards ModelsProspective StudiesRecombinant ProteinsStatistics, NonparametricSurvival RateTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionPrimary PCIST-segment elevation myocardial infarctionHORIZONS-AMI trialPercutaneous coronary interventionClinical outcomesCoronary interventionGlycoprotein IIb/IIIa inhibitorsMajor adverse cardiac eventsNet adverse clinical eventsIIb/IIIa inhibitorsAdverse cardiac eventsAdverse clinical eventsElevation myocardial infarctionPreferred reperfusion strategyPresentation of patientsInterventional hospitalMajor bleedingReperfusion strategyBalloon timeCardiac eventsCardiac deathPCI centerUnfractionated heparinMedian time
2009
Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
Dangas G, Mehran R, Guagliumi G, Caixeta A, Witzenbichler B, Aoki J, Peruga J, Brodie B, Dudek D, Kornowski R, Rabbani L, Parise H, Stone G, Investigators H. Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty Results From the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial. Journal Of The American College Of Cardiology 2009, 54: 1438-1446. PMID: 19796737, DOI: 10.1016/j.jacc.2009.06.021.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAngioplasty, BalloonAnticoagulantsClopidogrelConfidence IntervalsFemaleHirudinsHumansLogistic ModelsMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionPeptide FragmentsPlatelet Aggregation InhibitorsProportional Hazards ModelsRecombinant ProteinsTiclopidineTreatment OutcomeConceptsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionPrimary PCIGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsClopidogrel loading doseHORIZONS-AMI trialElevation myocardial infarctionLoading doseMyocardial infarctionAdverse cardiac event ratesMajor adverse cardiac eventsEvent ratesCardiac event rateLoading dose groupProbable stent thrombosisAdverse cardiac eventsAdverse event ratesPercutaneous coronary interventionHigher bleeding rateBivalirudin monotherapyPrimary angioplastyAnticoagulation regimensCardiac eventsCoronary intervention